PETQ vs. SVRA, ORIC, KYTX, CABA, EYPT, MNMD, ABUS, PHAR, HROW, and VREX
Should you be buying PetIQ stock or one of its competitors? The main competitors of PetIQ include Savara (SVRA), ORIC Pharmaceuticals (ORIC), Kyverna Therapeutics (KYTX), Cabaletta Bio (CABA), EyePoint Pharmaceuticals (EYPT), Mind Medicine (MindMed) (MNMD), Arbutus Biopharma (ABUS), Pharming Group (PHAR), Harrow (HROW), and Varex Imaging (VREX). These companies are all part of the "medical" sector.
PetIQ (NASDAQ:PETQ) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership.
PetIQ presently has a consensus price target of $29.00, indicating a potential upside of 45.66%. Savara has a consensus price target of $9.17, indicating a potential upside of 120.88%. Given Savara's higher probable upside, analysts plainly believe Savara is more favorable than PetIQ.
PetIQ has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.
In the previous week, Savara had 4 more articles in the media than PetIQ. MarketBeat recorded 6 mentions for Savara and 2 mentions for PetIQ. PetIQ's average media sentiment score of 1.88 beat Savara's score of 0.58 indicating that PetIQ is being referred to more favorably in the media.
PetIQ has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than PetIQ, indicating that it is currently the more affordable of the two stocks.
PetIQ has a net margin of 0.66% compared to Savara's net margin of 0.00%. PetIQ's return on equity of 13.33% beat Savara's return on equity.
95.0% of PetIQ shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 9.6% of PetIQ shares are held by company insiders. Comparatively, 5.1% of Savara shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
PetIQ received 21 more outperform votes than Savara when rated by MarketBeat users. However, 66.06% of users gave Savara an outperform vote while only 65.61% of users gave PetIQ an outperform vote.
Summary
PetIQ beats Savara on 12 of the 16 factors compared between the two stocks.
Get PetIQ News Delivered to You Automatically
Sign up to receive the latest news and ratings for PETQ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PETQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
